Skip to content

Anterior cutaneous branch of the femoral nerve, adductor canal, iPACK nerve block for postoperative analgesia after total knee arthroplasty: a single-center, randomized, double-blind controlled trial

Anterior cutaneous branch of the femoral nerve, adductor canal, iPACK nerve block for postoperative analgesia after total knee arthroplasty: a single-center, randomized, double-blind controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119201
Enrollment
Unknown
Registered
2026-02-24
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative analgesia after total knee arthroplasty

Interventions

Intervention Group:Postoperative analgesia with femoral nerve anterior branch, adductor canal, and iPACK combined nerve blocks plus intravenous analgesic pump
Control Group:Postoperative pain relief with a venous analgesic pump

Sponsors

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years, no gender restrictions; 2. Patients scheduled for primary total knee arthroplasty due to primary end-stage osteoarthritis; 3. Able to understand pain intensity assessment methods; 4. 18 kg/m² < BMI < 40 kg/m²; 5. Participants understand the purpose and procedures of this trial, voluntarily participate in this trial, and sign a written informed consent form..

Exclusion criteria

Exclusion criteria: 1. Individuals with a history of allergy to local anesthetics or opioids; 2. Infection at the puncture site or neurological disorders; 3. Individuals with major cardiovascular diseases, liver or kidney dysfunction, or coagulation disorders; 4. ASA classification IV or above; 5. Individuals addicted to opioids; 6. Those deemed unsuitable to participate in this trial by the investigator.

Design outcomes

Primary

MeasureTime frame
Morphine consumption;

Secondary

MeasureTime frame
Pain Score;First time getting out of bed;Discharge time;Quadriceps strength;Adverse reactions (nausea, vomiting, urinary retention, etc.);Patient satisfaction;

Countries

China

Contacts

Public ContactLu Jing

Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

Lujing.1979@hotmail.com+86 177 0813 0227

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026